Condition: Pancreatic Ductal Adenocarcinoma · Gastric Cancer · Esophageal Cancer · Sponsor: Perspective Therapeutics
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
This description comes directly from the study's public registry record.
ClinicalTrials at Perspectivetherapeutics · (206) 676-0900 · clinicaltrials@perspectivetherapeutics.com
Always discuss trial participation with your own doctor first.
| University of Miami | Miami, Florida, United States | Recruiting |
| Biogenix | Miami, Florida, United States | Recruiting |
| University of Kansas | Kansas City, Kansas, United States | Recruiting |
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
| Mayo Clinic in Rochester, Minnesota | Rochester, Minnesota, United States | Recruiting |
| Saint Louis University | St Louis, Missouri, United States | Recruiting |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Wisconsin | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06710756